Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | withdrawn | Phase 1 / Phase 2 | 0 | Baptist Health South FloridaOTHER | 1 | Sep 19, 2024 |
| NCT03473925 | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | completed | Phase 2 | 107 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Aug 28, 2024 | clinicaltrials |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | terminated | Phase 2 | 10 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | terminated | Phase 2 | 8 | Jodi Layton, MDOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT04408924 | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer(CYCLONE 1) | completed | Phase 2 | 44 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer | terminated | Phase 2 | 16 | Effector TherapeuticsINDUSTRY | 1 | Jun 21, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04458311 | Abiraterone Acetate in Combination With Tildrakizumab(ACTIon) | terminated | Phase 1 / Phase 2 | 13 | Institute of Cancer Research, United KingdomOTHER | 2 | Apr 25, 2024 | clinicaltrials |
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT05445882 | N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05034562 | Gallium-68 PSMA-11 PET in Participants With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03554317 | COMbination of Bipolar Androgen Therapy and Nivolumab(COMBAT-CRPC) | completed | Phase 2 | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT03878823 | Safety and Pharmacokinetics of ODM-209(STESIDES) | completed | Phase 1 / Phase 2 | 38 | Orion Corporation, Orion PharmaINDUSTRY | 3 | Feb 1, 2024 | clinicaltrials |
| NCT03698370 | Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer | completed | Phase 2 | 27 | Andrei IagaruOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03113617 | 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | completed | Phase 2 | 44 | Andrei IagaruOTHER | 1 | Dec 12, 2023 | clinicaltrials |
| NCT00915122 | Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate | completed | Phase 1 / Phase 2 | 81 | University Health Network, TorontoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT01972217 | Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | completed | Phase 2 | 158 | AstraZenecaINDUSTRY | 11 | Nov 14, 2023 | clinicaltrials |
| NCT03396874 | Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | completed | Phase 2 | 1,435 | University of MichiganOTHER | 1 | Nov 3, 2023 | clinicaltrials |
| NCT05405439 | To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 3, 2023 | clinicaltrials |
| NCT00020046 | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | — | National Institutes of Health Clinical Center (CC)NIH | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03830164 | Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03999515 | Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | terminated | Phase 2 | 3 | University of WashingtonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03752099 | To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 80 | Veru Inc.INDUSTRY | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01093183 | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 25 | University of NebraskaOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT05489991 | A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | terminated | Phase 1 / Phase 2 | 1 | Tceleron Therapeutics, Inc.INDUSTRY | 1 | Aug 18, 2023 | clinicaltrials |
| NCT02499835 | Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 66 | University of Wisconsin, MadisonOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT03658447 | PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)(PRINCE) | completed | Phase 1 / Phase 2 | 37 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jul 28, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT02326805 | PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | completed | Phase 2 | 154 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2023 | clinicaltrials |
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05549778 | Polaprezinc Treatment for Enzalutamide- or Abiraterone-resistant CRPC(PEACe) | completed | Phase 1 / Phase 2 | 12 | Jiangnan UniversityOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT04676607 | SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | completed | Phase 2 | 6 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT02516670 | Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials